


Remarks

In the Communication dated 15 November 2006, the Applicants' election of Group I, claims 1-15, 20, and 21 was acknowledged and treated as made without traverse. In addition, the scope of the elected subject matter was identified as follows: referring to the compound of formula 1 in claim 1:



where A1-A5 are as defined; Q is a carbocyclic group; T is as defined; m and n are as defined; and R¹-R¹⁰, R⁹⁹, and R¹⁰⁰ are as defined but not heterocyclic. [For the present submission, the Applicants have also amended R⁷⁷ to be as defined but not to include heterocycle.]

As a result of the above identified elected subject matter, objections were raised for claims 1-15, 20, and 21. In this Response, claims 1, 10, and 14 have been amended; and claims 3, 4, 8, and 9 have been canceled.

Applicants reserve the right to file one or more continuing applications.

Additionally, the Applicants request rejoinder of the method claims 16-19 under MPEP §821.04 upon indication of allowable subject matter.

Please change the Attorney Docket Number to X-17600.

The Applicants request timely examination of the elected invention. The Examiner is invited to contact the undersigned attorney by telephone if there are any questions about this

submission or other issues that may be resolved in that fashion.

Respectfully submitted,

/James B. Myers/
James B. Myers
Attorney for Applicants
Registration No. 42,021
Phone: 317-276-0755

Eli Lilly and Company

Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

15 February 2007